Literature DB >> 19375554

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

Bernard M Y Cheung1, Kwok Leung Ong, Stacey S Cherny, Pak-Chung Sham, Annette W K Tso, Karen S L Lam.   

Abstract

OBJECTIVE: Changes in the prevalence, treatment, and management of diabetes in the United States from 1999 to 2006 were studied using data from the National Health and Nutrition Examination Survey.
METHODS: Data on 17,306 participants aged 20 years or more were analyzed. Glycemic, blood pressure, and cholesterol targets were glycosylated hemoglobin less than 7.0%, blood pressure less than 130/80 mm Hg, and low-density lipoprotein (LDL) cholesterol less than 100 mg/dL, respectively.
RESULTS: The prevalence of diagnosed diabetes was 6.5% from 1999 to 2002 and 7.8% from 2003 to 2006 (P < .05) and increased significantly in women, non-Hispanic whites, and obese people. Although there were no significant changes in the pattern of antidiabetic treatment, the age-adjusted percentage of people with diagnosed diabetes achieving glycemic and LDL targets increased from 43.1% to 57.1% (P < .05) and from 36.1% to 46.5% (P < .05), respectively. Glycosylated hemoglobin decreased from 7.62% to 7.15% during this period (P < .05). The age-adjusted percentage achieving all 3 targets increased insignificantly from 7.0% to 12.2%.
CONCLUSIONS: The prevalence of diagnosed diabetes increased significantly from 1999 to 2006. The proportion of people with diagnosed diabetes achieving glycemic and LDL targets also increased. However, there is a need to achieve glycemic, blood pressure, and LDL targets simultaneously.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375554     DOI: 10.1016/j.amjmed.2008.09.047

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  129 in total

1.  Renal function and healthcare costs in patients with polycystic kidney disease.

Authors:  Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus.

Authors:  Jaime A Davidson
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

4.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

5.  Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2015-03

6.  Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2015-03

Review 7.  The role of bile acid sequestrants in the management of type 2 diabetes mellitus.

Authors:  Om P Ganda
Journal:  Metab Syndr Relat Disord       Date:  2010-10-29       Impact factor: 1.894

8.  Bile acid sequestrants and diabetes: introduction and overview to the supplement.

Authors:  I Jialal
Journal:  Metab Syndr Relat Disord       Date:  2010-10-25       Impact factor: 1.894

9.  Risk perception and self-management in urban, diverse adults with type 2 diabetes: the improving diabetes outcomes study.

Authors:  Erica Shreck; Jeffrey S Gonzalez; Hillel W Cohen; Elizabeth A Walker
Journal:  Int J Behav Med       Date:  2014-02

10.  Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and dyslipidemia in morbidly obese patients who present for bariatric surgery.

Authors:  Rouzbeh Mostaedi; Denise E Lackey; Sean H Adams; Stephen A Dada; Zahid A Hoda; Mohamed R Ali
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.